quantitative bisulfite-pcr pyrosequencing Search Results


99
Zymo Research ez dna methylation kit
11p15.5 epigenetic and genetic states and expression of CDKN1C in breast cancer cells. (A) The <t>DNA</t> methylation status of the 11p15.5 ICR differentially methylated domain was analyzed by <t>high-resolution</t> <t>bisulfite</t> PCR pyrosequencing in primary tumors (n = 306), breast cancer cell lines (n = 52) and normal breast tissues (n = 19). Methylation levels of individual CpG sites (circles) are shown in a color gradient ranging from 0% (white) to 100% (blue). Left, diagram of CpG sites interrogated by the pyrosequencing assay. Right, results presented in rows of columns. (B) Multiple linear regression analysis of impact of 11p15.5 ICR methylation and genetic status on CDKN1C expression in breast cancer cells. The combined 11p15.5 ICR methylation, copy number and CDKN1C mRNA levels in 16 breast cancer cell lines were assessed by bisulfite PCR pyrosequencing, DNA copy number qPCR and qRT–PCR, respectively. DNA copy number of 11p15.5 ICR was quantified by absolute standard curve of cloned PCR products as described in supplementary Figure S4 (available at Carcinogenesis Online). Relative CDKN1C ΔCt expression values were obtained by normalizing to the 36B4 reference gene. (C) The effect of E2 on CDKN1C expression in breast cancer cells with 11p15.5 ICR hypermethylation. MDA-MB-453 and T47D cells were stimulated with 10 nM E2 or vehicle for 12 h. CDKN1C mRNA levels were assessed as described in Figure 1. Results are the average of two independent experiments. Columns, mean (n = 6); bars, SD.
Ez Dna Methylation Kit, supplied by Zymo Research, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ez dna methylation kit/product/Zymo Research
Average 99 stars, based on 1 article reviews
ez dna methylation kit - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

90
Qiagen pcr bisulfite-modified genomic dna epitect bisulfite kit
11p15.5 epigenetic and genetic states and expression of CDKN1C in breast cancer cells. (A) The <t>DNA</t> methylation status of the 11p15.5 ICR differentially methylated domain was analyzed by <t>high-resolution</t> <t>bisulfite</t> PCR pyrosequencing in primary tumors (n = 306), breast cancer cell lines (n = 52) and normal breast tissues (n = 19). Methylation levels of individual CpG sites (circles) are shown in a color gradient ranging from 0% (white) to 100% (blue). Left, diagram of CpG sites interrogated by the pyrosequencing assay. Right, results presented in rows of columns. (B) Multiple linear regression analysis of impact of 11p15.5 ICR methylation and genetic status on CDKN1C expression in breast cancer cells. The combined 11p15.5 ICR methylation, copy number and CDKN1C mRNA levels in 16 breast cancer cell lines were assessed by bisulfite PCR pyrosequencing, DNA copy number qPCR and qRT–PCR, respectively. DNA copy number of 11p15.5 ICR was quantified by absolute standard curve of cloned PCR products as described in supplementary Figure S4 (available at Carcinogenesis Online). Relative CDKN1C ΔCt expression values were obtained by normalizing to the 36B4 reference gene. (C) The effect of E2 on CDKN1C expression in breast cancer cells with 11p15.5 ICR hypermethylation. MDA-MB-453 and T47D cells were stimulated with 10 nM E2 or vehicle for 12 h. CDKN1C mRNA levels were assessed as described in Figure 1. Results are the average of two independent experiments. Columns, mean (n = 6); bars, SD.
Pcr Bisulfite Modified Genomic Dna Epitect Bisulfite Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr bisulfite-modified genomic dna epitect bisulfite kit/product/Qiagen
Average 90 stars, based on 1 article reviews
pcr bisulfite-modified genomic dna epitect bisulfite kit - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc bisulfite-pcr pyrosequencing method
11p15.5 epigenetic and genetic states and expression of CDKN1C in breast cancer cells. (A) The <t>DNA</t> methylation status of the 11p15.5 ICR differentially methylated domain was analyzed by <t>high-resolution</t> <t>bisulfite</t> PCR pyrosequencing in primary tumors (n = 306), breast cancer cell lines (n = 52) and normal breast tissues (n = 19). Methylation levels of individual CpG sites (circles) are shown in a color gradient ranging from 0% (white) to 100% (blue). Left, diagram of CpG sites interrogated by the pyrosequencing assay. Right, results presented in rows of columns. (B) Multiple linear regression analysis of impact of 11p15.5 ICR methylation and genetic status on CDKN1C expression in breast cancer cells. The combined 11p15.5 ICR methylation, copy number and CDKN1C mRNA levels in 16 breast cancer cell lines were assessed by bisulfite PCR pyrosequencing, DNA copy number qPCR and qRT–PCR, respectively. DNA copy number of 11p15.5 ICR was quantified by absolute standard curve of cloned PCR products as described in supplementary Figure S4 (available at Carcinogenesis Online). Relative CDKN1C ΔCt expression values were obtained by normalizing to the 36B4 reference gene. (C) The effect of E2 on CDKN1C expression in breast cancer cells with 11p15.5 ICR hypermethylation. MDA-MB-453 and T47D cells were stimulated with 10 nM E2 or vehicle for 12 h. CDKN1C mRNA levels were assessed as described in Figure 1. Results are the average of two independent experiments. Columns, mean (n = 6); bars, SD.
Bisulfite Pcr Pyrosequencing Method, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bisulfite-pcr pyrosequencing method/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
bisulfite-pcr pyrosequencing method - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc bisulfite-sequencing
Immunoepigenetic-based studies in bladder cancer.
Bisulfite Sequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bisulfite-sequencing/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
bisulfite-sequencing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc highly quantitative bisulfite-pcr
Immunoepigenetic-based studies in bladder cancer.
Highly Quantitative Bisulfite Pcr, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/highly quantitative bisulfite-pcr/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
highly quantitative bisulfite-pcr - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc bisulphite-polymerase chain reaction
Immunoepigenetic-based studies in bladder cancer.
Bisulphite Polymerase Chain Reaction, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bisulphite-polymerase chain reaction/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
bisulphite-polymerase chain reaction - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc pyromak q24 pyrosequencing system
Immunoepigenetic-based studies in bladder cancer.
Pyromak Q24 Pyrosequencing System, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pyromak q24 pyrosequencing system/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
pyromak q24 pyrosequencing system - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Illumina Inc amplicon deep sequencing
Immunoepigenetic-based studies in bladder cancer.
Amplicon Deep Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amplicon deep sequencing/product/Illumina Inc
Average 90 stars, based on 1 article reviews
amplicon deep sequencing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc quantitative bisulfite pyrosequencing
Immunoepigenetic-based studies in bladder cancer.
Quantitative Bisulfite Pyrosequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantitative bisulfite pyrosequencing/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
quantitative bisulfite pyrosequencing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc polymerase chain reaction (pcr)-pyrosequencing
Immunoepigenetic-based studies in bladder cancer.
Polymerase Chain Reaction (Pcr) Pyrosequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polymerase chain reaction (pcr)-pyrosequencing/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
polymerase chain reaction (pcr)-pyrosequencing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
agena bioscience epityper
Immunoepigenetic-based studies in bladder cancer.
Epityper, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/epityper/product/agena bioscience
Average 90 stars, based on 1 article reviews
epityper - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Pyrosequencing Inc pcr pyrosequencing
Immunoepigenetic-based studies in bladder cancer.
Pcr Pyrosequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr pyrosequencing/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
pcr pyrosequencing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


11p15.5 epigenetic and genetic states and expression of CDKN1C in breast cancer cells. (A) The DNA methylation status of the 11p15.5 ICR differentially methylated domain was analyzed by high-resolution bisulfite PCR pyrosequencing in primary tumors (n = 306), breast cancer cell lines (n = 52) and normal breast tissues (n = 19). Methylation levels of individual CpG sites (circles) are shown in a color gradient ranging from 0% (white) to 100% (blue). Left, diagram of CpG sites interrogated by the pyrosequencing assay. Right, results presented in rows of columns. (B) Multiple linear regression analysis of impact of 11p15.5 ICR methylation and genetic status on CDKN1C expression in breast cancer cells. The combined 11p15.5 ICR methylation, copy number and CDKN1C mRNA levels in 16 breast cancer cell lines were assessed by bisulfite PCR pyrosequencing, DNA copy number qPCR and qRT–PCR, respectively. DNA copy number of 11p15.5 ICR was quantified by absolute standard curve of cloned PCR products as described in supplementary Figure S4 (available at Carcinogenesis Online). Relative CDKN1C ΔCt expression values were obtained by normalizing to the 36B4 reference gene. (C) The effect of E2 on CDKN1C expression in breast cancer cells with 11p15.5 ICR hypermethylation. MDA-MB-453 and T47D cells were stimulated with 10 nM E2 or vehicle for 12 h. CDKN1C mRNA levels were assessed as described in Figure 1. Results are the average of two independent experiments. Columns, mean (n = 6); bars, SD.

Journal: Carcinogenesis

Article Title: Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells

doi: 10.1093/carcin/bgr017

Figure Lengend Snippet: 11p15.5 epigenetic and genetic states and expression of CDKN1C in breast cancer cells. (A) The DNA methylation status of the 11p15.5 ICR differentially methylated domain was analyzed by high-resolution bisulfite PCR pyrosequencing in primary tumors (n = 306), breast cancer cell lines (n = 52) and normal breast tissues (n = 19). Methylation levels of individual CpG sites (circles) are shown in a color gradient ranging from 0% (white) to 100% (blue). Left, diagram of CpG sites interrogated by the pyrosequencing assay. Right, results presented in rows of columns. (B) Multiple linear regression analysis of impact of 11p15.5 ICR methylation and genetic status on CDKN1C expression in breast cancer cells. The combined 11p15.5 ICR methylation, copy number and CDKN1C mRNA levels in 16 breast cancer cell lines were assessed by bisulfite PCR pyrosequencing, DNA copy number qPCR and qRT–PCR, respectively. DNA copy number of 11p15.5 ICR was quantified by absolute standard curve of cloned PCR products as described in supplementary Figure S4 (available at Carcinogenesis Online). Relative CDKN1C ΔCt expression values were obtained by normalizing to the 36B4 reference gene. (C) The effect of E2 on CDKN1C expression in breast cancer cells with 11p15.5 ICR hypermethylation. MDA-MB-453 and T47D cells were stimulated with 10 nM E2 or vehicle for 12 h. CDKN1C mRNA levels were assessed as described in Figure 1. Results are the average of two independent experiments. Columns, mean (n = 6); bars, SD.

Article Snippet: Approximately 300 ng of genomic DNA was bisulfite modified with EZ DNA Methylation Kit (Zymo Research, Irivine, CA) according to the manufacturer’s protocol.

Techniques: Expressing, DNA Methylation Assay, Methylation, Pyrosequencing Assay, Quantitative RT-PCR, Clone Assay

Potential mechanisms causing repression of CDKN1C in breast cancer cells. (A) Proposed model for epigenetic repression of CDKN1C through coordinated loop formation with the 11p15.5 ICR. CTCF binding to the ICR and CDKN1C locus and forms a long-range intrachromosomal loop via dimerization of CTCF. Ligand-bound ERα complex (orange and blue sphere) may mediate silencing through the formation of a secondary loop that serves both to sequester upstream tissue-specific enhancers and to recruit PRC2 and HDAC1 to the 11p15.5 ICR. CTCF serves as a scaffold to secure the PRC2 complex that methylates H3K27, leading to the formation of a repressive chromatin state at the CDKN1C locus. (B) Proposed regulatory mechanism of CDKN1C-AS. The formation of a double-stranded RNA may negatively regulate stability, transport and/or translation of the sense CDKN1C transcript. (C) Summary of three potential mechanisms causing CDKN1C repression in breast cancer cells. DNA methylation status of 11p15.5 ICR is indicated by large oval: white (unmethylated), black (methylated). Upper left, in the normal imprinted domain unmethylated 11p15.5 ICR on the paternal allele (♂) functions as a silencer and a promoter for KCNQ1OT1 transcription, repressing CDKN1C expression. The methylated maternal allele (♀) cannot function as a silencer or a promoter for KCNQ1OT1, thus permitting expression of CDKN1C. Upper right, the CDKN1C-AS transcript represses CDKN1C in trans, potentially through a double-stranded RNA mechanism. Under certain cellular conditions, this may be induced by estrogen-mediated upregulation of CDKN1C-AS. Lower left, DNA hypomethylation resulting from genetic loss of the methylated 11p15.5 ICR allele leads to aberrant domain silencer activity mediated by unrestricted CTCF binding and KCNQ1OT1 transcription, repressing CDKN1C expression. Lower right, estrogen induces KCNQ1OT1 transcription and CTCF recruitment to mediate ICR silencer activity, which in turn direct epigenetic repression of the CDKN1C locus.

Journal: Carcinogenesis

Article Title: Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells

doi: 10.1093/carcin/bgr017

Figure Lengend Snippet: Potential mechanisms causing repression of CDKN1C in breast cancer cells. (A) Proposed model for epigenetic repression of CDKN1C through coordinated loop formation with the 11p15.5 ICR. CTCF binding to the ICR and CDKN1C locus and forms a long-range intrachromosomal loop via dimerization of CTCF. Ligand-bound ERα complex (orange and blue sphere) may mediate silencing through the formation of a secondary loop that serves both to sequester upstream tissue-specific enhancers and to recruit PRC2 and HDAC1 to the 11p15.5 ICR. CTCF serves as a scaffold to secure the PRC2 complex that methylates H3K27, leading to the formation of a repressive chromatin state at the CDKN1C locus. (B) Proposed regulatory mechanism of CDKN1C-AS. The formation of a double-stranded RNA may negatively regulate stability, transport and/or translation of the sense CDKN1C transcript. (C) Summary of three potential mechanisms causing CDKN1C repression in breast cancer cells. DNA methylation status of 11p15.5 ICR is indicated by large oval: white (unmethylated), black (methylated). Upper left, in the normal imprinted domain unmethylated 11p15.5 ICR on the paternal allele (♂) functions as a silencer and a promoter for KCNQ1OT1 transcription, repressing CDKN1C expression. The methylated maternal allele (♀) cannot function as a silencer or a promoter for KCNQ1OT1, thus permitting expression of CDKN1C. Upper right, the CDKN1C-AS transcript represses CDKN1C in trans, potentially through a double-stranded RNA mechanism. Under certain cellular conditions, this may be induced by estrogen-mediated upregulation of CDKN1C-AS. Lower left, DNA hypomethylation resulting from genetic loss of the methylated 11p15.5 ICR allele leads to aberrant domain silencer activity mediated by unrestricted CTCF binding and KCNQ1OT1 transcription, repressing CDKN1C expression. Lower right, estrogen induces KCNQ1OT1 transcription and CTCF recruitment to mediate ICR silencer activity, which in turn direct epigenetic repression of the CDKN1C locus.

Article Snippet: Approximately 300 ng of genomic DNA was bisulfite modified with EZ DNA Methylation Kit (Zymo Research, Irivine, CA) according to the manufacturer’s protocol.

Techniques: Binding Assay, DNA Methylation Assay, Methylation, Expressing, Activity Assay

Immunoepigenetic-based studies in bladder cancer.

Journal: International Journal of Molecular Sciences

Article Title: Targeting the Immune system and Epigenetic Landscape of Urological Tumors

doi: 10.3390/ijms21030829

Figure Lengend Snippet: Immunoepigenetic-based studies in bladder cancer.

Article Snippet: Methylation , DEFB1 (mediator of innate immunity) , Epigenetic regulation of DEFB1 by promoter methylation , Bisulfite-sequencing Pyrosequencing RT-qPCR IHC WB , Tissues ( n = 60 patients) + in vitro (cell lines) , Lee J, 2016 [ ] .

Techniques: Methylation, Expressing, DNA Methylation Assay, Enzyme-linked Immunosorbent Assay, In Vitro, CpG Methylation Assay, Knock-Out, CRISPR, In Vivo, Inhibition

Immunoepigenetic-based studies in Kidney Cancer.

Journal: International Journal of Molecular Sciences

Article Title: Targeting the Immune system and Epigenetic Landscape of Urological Tumors

doi: 10.3390/ijms21030829

Figure Lengend Snippet: Immunoepigenetic-based studies in Kidney Cancer.

Article Snippet: Methylation , DEFB1 (mediator of innate immunity) , Epigenetic regulation of DEFB1 by promoter methylation , Bisulfite-sequencing Pyrosequencing RT-qPCR IHC WB , Tissues ( n = 60 patients) + in vitro (cell lines) , Lee J, 2016 [ ] .

Techniques: Methylation, Activity Assay, Microarray, In Vitro, In Vivo, Gene Expression, Expressing

Immunoepigenetic-based studies in Prostate Cancer.

Journal: International Journal of Molecular Sciences

Article Title: Targeting the Immune system and Epigenetic Landscape of Urological Tumors

doi: 10.3390/ijms21030829

Figure Lengend Snippet: Immunoepigenetic-based studies in Prostate Cancer.

Article Snippet: Methylation , DEFB1 (mediator of innate immunity) , Epigenetic regulation of DEFB1 by promoter methylation , Bisulfite-sequencing Pyrosequencing RT-qPCR IHC WB , Tissues ( n = 60 patients) + in vitro (cell lines) , Lee J, 2016 [ ] .

Techniques: Methylation, Expressing, Northern Blot, In Vitro, Affinity Chromatography, Methylation Sequencing, Migration, In Vivo, Lysis, Blocking Assay, Infection, DNA Sequencing, Ex Vivo, Microarray, Enzyme-linked Immunosorbent Assay, Inhibition, Immunohistochemistry-IF